| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 03:01 UTC | Report an error |
|---|
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 03:01 UTC | Report an error |
|---|
| State of incorporation | NV | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 03:01 UTC | Report an error |
|---|
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 03:01 UTC | Report an error |
|---|
| Business address | 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM, NC, 27703 | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 03:01 UTC | Report an error |
|---|
| Exchanges | NYSE | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 03:01 UTC | Report an error |
|---|
| Revenue (fiscal year ended 2025-12-31) | $16,795,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | 2026-11-22 03:01 UTC | Report an error |
|---|
| Net income (loss) (fiscal year ended 2025-12-31) | $-43,319,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | 2026-11-22 03:01 UTC | Report an error |
|---|
| Total assets (at 2025-12-31) | $130,397,000 | 2025-12-31 | 10-K, XBRL Assets | 2026-11-22 03:01 UTC | Report an error |
|---|
| Stockholders' equity (at 2025-12-31) | $38,881,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | 2026-11-22 03:01 UTC | Report an error |
|---|
| Cash and cash equivalents (at 2025-12-31) | $17,973,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | 2026-11-22 03:01 UTC | Report an error |
|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $-22,590,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | 2026-11-22 03:01 UTC | Report an error |
|---|
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $99,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | 2026-11-22 03:01 UTC | Report an error |
|---|
| Operating lease liabilities (at 2025-12-31) | $3,387,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | 2026-11-22 03:01 UTC | Report an error |
|---|
| Form D total offering amount (D filed 2026-11-16) | $57,500,000 | 2026-11-16 | D | 2026-11-22 03:01 UTC | Report an error |
|---|
| Form D total amount sold (D filed 2026-11-16) | $57,500,000 | 2026-11-16 | D | 2026-11-22 03:01 UTC | Report an error |
|---|
| Form D industry group | Pharmaceuticals | 2026-11-16 | D | 2026-11-22 03:01 UTC | Report an error |
|---|
| Form D revenue range | Decline to Disclose | 2026-11-16 | D | 2026-11-22 03:01 UTC | Report an error |
|---|
| Form D date of first sale | 2026-10-30 | 2026-11-16 | D | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-12) | On November 12, 2026, Pelthos Therapeutics Inc. (the “Company”) issued a press release summarizing its financial results for the three and nine months ended September 30, 2026, as well as providing an update on the Company’s operations. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the… | 2026-11-12 | SEC EDGAR 8-K 0001919246-26-000134 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-30) | Merger Agreement On October 30, 2026, Pelthos Therapeutics Inc., a Nevada corporation (“Pelthos” or “Public Company”), Credit Card Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Pelthos (“Merger Sub”), Credit Card Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Pelthos (“Merger Sub II”), Castle Creek Biosciences, Inc., a Delaware corporation (“Castle Creek” or “Merger Partner”), and Paragon Biosciences, LLC, a Delaware limited liability company, as the securityholder representative (the “Securityholder Representative”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other… | 2026-10-30 | SEC EDGAR 8-K 0001104659-26-120457 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 2.03, Creation of a Direct Financial Obligation or an Obligation (filed 2026-10-30) | under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 is incorporated into this Item 2.03 by reference. | 2026-10-30 | SEC EDGAR 8-K 0001104659-26-120457 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-10-30) | The securities to be sold to the PIPE Investors, the Option Buyer and any Other Bridge Buyers will not be registered under the Securities Act, and will be issued and sold in reliance on the exemption from registration requirements thereof provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder as a transaction by an issuer not involving a public offering. The shares of Pelthos Common Stock to be issued in the First Merger are expected to be registered under the Securities Act pursuant to the Form S-4. The disclosure set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. | 2026-10-30 | SEC EDGAR 8-K 0001104659-26-120457 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 3.03, Material Modification to Rights of Security Holders (filed 2026-10-30) | The information set forth in Item 5.03 below is incorporated herein by reference. | 2026-10-30 | SEC EDGAR 8-K 0001104659-26-120457 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 5.02, Departure of Directors or Certain Officers; Election of (filed 2026-10-30) | Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment to CEO Employment Agreement On October 30, 2026, Pelthos and Scott Plesha, its Chief Executive Officer, entered into a Second Amendment to his Executive Employment Agreement dated as of July 1, 2025, as amended (the “Plesha Amendment”). The Plesha Amendment expands Mr. Plesha’s severance benefits by providing for a prorated annual bonus based on actual performance, for the year in which Mr. Plesha’s employment terminates. The foregoing description is qualified in its entirety by reference to the full text of the agreement, which is filed as Exhibit 10.9 to this Current Report on Form 8-K and… | 2026-10-30 | SEC EDGAR 8-K 0001104659-26-120457 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 5.03, Amendments to Articles of Incorporation or Bylaws; Change (filed 2026-10-30) | in Fiscal Year. On October 30, 2026, following the Board’s approval of an amendment (the “Amendment”) to the Certificate of Designation of Rights and Preferences of Series A Convertible Preferred Stock (the “Series A Certificate of Designation”), the Company’s stockholders and the Required Holders (as defined in the Series A Certificate of Designation) approved the Amendment. The Amendment will make certain modifications to the provisions relating to Pelthos’ failure to timely deliver shares of common stock upon conversion of the Series A Preferred Stock, and to the Company’s obligations upon the occurrence of a fundamental transaction. The foregoing description of the Amendment does not… | 2026-10-30 | SEC EDGAR 8-K 0001104659-26-120457 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 5.07, Submission of Matters to a Vote of Security Holders (filed 2026-10-30) | The disclosure set forth above in the paragraph titled “Stockholder Approval of Transaction” in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.07. | 2026-10-30 | SEC EDGAR 8-K 0001104659-26-120457 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-30) | On October 30, 2026, Pelthos issued a press release announcing the execution of the Merger Agreement and the Securities Purchase Agreement. The press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference. | 2026-10-30 | SEC EDGAR 8-K 0001104659-26-120457 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 5.07, Submission of Matters to a Vote of Security Holders (filed 2026-10-01) | On September 29, 2026, the Company held its 2026 Annual Meeting. Set forth below are the three proposals that were voted on at the Annual Meeting and the stockholder votes on each such proposal, as certified by the inspector of elections for the Annual Meeting. These proposals are described in further detail in the Proxy Statement. As of the close of business on August 4, 2026 (the “Record Date”), 3,828,469 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and 52,128 shares of the Company’s Series A Preferred Stock, par value $0.0001 per share (“Series A Preferred Stock”) were issued and outstanding. Each stockholder as of the Record Date was entitled to… | 2026-10-01 | SEC EDGAR 8-K 0001919246-26-000125 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-13) | On August 13, 2026, Pelthos Therapeutics Inc. (the “Company”) issued a press release summarizing its financial results for the second quarter 2026, as well as providing an update on the Company’s operations. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference. Readers are encouraged to review the Company's Current Report on Form 8-K filed under Item 4.02 (Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review), which describes the Company's determination that its previously issued condensed consolidated financial statements for the quarter ended March 31, 2026… | 2026-08-13 | SEC EDGAR 8-K 0001919246-26-000112 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| 8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-13) | The information disclosed in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is incorporated into this Item 7.01 by reference. On August 13, 2026, the Company made available a presentation on its website. A copy of the presentation is attached hereto as Exhibit 99.2. Information contained on the Company’s website is not incorporated by reference into and should not be considered to be part of this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibit 99.2 attached hereto, which is incorporated into this Item 7.01 by reference, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange… | 2026-08-13 | SEC EDGAR 8-K 0001919246-26-000112 (text as filed, excerpt) | 2026-11-22 03:01 UTC | Report an error |
|---|
| Largest institutional holder #1 (13F as filed): AIGH Capital Management LLC | $9,300,309 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 03:01 UTC | Report an error |
|---|
| Largest institutional holder #2 (13F as filed): Murchinson Ltd. | $8,599,575 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 03:01 UTC | Report an error |
|---|
| Largest institutional holder #3 (13F as filed): Ikarian Capital, LLC | $7,251,459 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 03:01 UTC | Report an error |
|---|
| Largest institutional holder #4 (13F as filed): BOOTHBAY FUND MANAGEMENT, LLC | $2,881,842 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 03:01 UTC | Report an error |
|---|
| Largest institutional holder #5 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC | $2,745,007 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 03:01 UTC | Report an error |
|---|
| Largest institutional holder #6 (13F as filed): CANTOR FITZGERALD, L. P. | $2,154,712 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 03:01 UTC | Report an error |
|---|
| Largest institutional holder #7 (13F as filed): J. Goldman & Co LP | $1,076,000 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 03:01 UTC | Report an error |
|---|
| Largest institutional holder #8 (13F as filed): DIADEMA PARTNERS LP | $700,085 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 03:01 UTC | Report an error |
|---|
| Largest institutional holder #9 (13F as filed): WEXFORD CAPITAL LP | $632,007 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 03:01 UTC | Report an error |
|---|
| Largest institutional holder #10 (13F as filed): CITADEL ADVISORS LLC | $425,200 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 03:01 UTC | Report an error |
|---|